Evidence map›Paper›PMID 31385046›Full record

ArticleEuropean radiology2020

Prediction of extraprostatic extension on multi-parametric magnetic resonance imaging in patients with anterior prostate cancer.

Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Hyoung Sim Suh, Gheeyoung Choe, Seok-Soo Byun, Sung Kyu Hong, Sangchul Lee, Joongyub Lee

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hyungwoo AhnDepartment of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
Sung Il HwangDepartment of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea. hwangsi49@gmail.com.ORCID http://orcid.org/0000-0001-7516-5369
Hak Jong LeeDepartment of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
Hyoung Sim SuhDepartment of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
Gheeyoung ChoeDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
Seok-Soo ByunDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
Sung Kyu HongDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
Sangchul LeeDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
Joongyub LeeDepartment of Prevention and Management, School of Medicine, Inha University Hospital, Incheon, South Korea.

Funding

Ministry of Science, Information and Communications Technology (KR) NRF-2013R1A1A2011398Seoul National University Bundang Hospital (KR) 11-2010-008
6 · The paper itself

Abstract

objectivesTo validate how established markers of extraprostatic extension (EPE) are applied to anterior prostate cancers (APCs), and to investigate other novel markers if available.

methodsAmong 614 histopathologically confirmed APCs from 2011 to 2016, 221 lesions with PiRADS (verion 2) scores ≥ 4 on 3-T multi-parametric MRI were analyzed retrospectively. Two radiologists independently assessed capsular morphology qualitatively with 5-point scale (normal, thinning, bulging, loss, extracapsular disease), and capsule contact length (arc), tumor dimension, and their ratio (arc-dimension ratio) quantitatively. Reproducibility in measurement was assessed with κ and intra-class correlation coefficients (ICCs). Logistic regression analysis was done to find meaningful indicators of EPE. Diagnostic performance of markers was compared to one another with generalized linear model and multi-reader multi-case ROC analysis.

resultsReproducibility was moderate to substantial (κ 0.45-0.73) for qualitative, and moderate to almost perfect (ICC 0.50-0.87) for quantitative features of EPE. Capsular morphology (odds ratio [OR] 1.818), capsule contact length (OR 1.115), tumor dimension (OR 1.035), and arc-dimension ratio (OR 1.846) were independently associated with EPE (p ≤ 0.019). Capsular bulging and capsule contact length of 10 mm as thresholds of EPE demonstrated sensitivity/specificity of 0.58/0.85 and 0.77/0.68, respectively. Capsule contact length yielded greatest AUC (0.784), followed by capsular morphology (0.778), arc-dimension ratio (0.749), and tumor dimension (0.741). Diagnostic performance of capsular morphology, capsule contact length, and arc-dimension ratio was comparable in predicting EPE.

conclusionsExisting markers of EPE applicable regardless of locations of tumors apply similarly to APCs. Arc-dimension ratio may be a novel marker of EPE of APCs. KEY POINTS: • Existing imaging markers of extraprostatic extension (EPE) which have been applied regardless of locations of tumors are reflected similarly to anterior prostate cancers (APCs). • Measuring tumor dimension without capsular assessment may result in insufficient pre-operative prediction of EPE of APCs. • Arc-dimension ratio (capsule contact length divided by tumor dimension) exhibited highest OR and comparable performance to existing features in predicting EPE of APCs.

Indexed as

AgedHumansMaleMiddle AgedMultiparametric Magnetic Resonance ImagingProstateProstatectomyProstatic NeoplasmsReproducibility of ResultsRetrospective StudiesROC CurveSensitivity and SpecificityAdenocarcinomaMagnetic resonance imagingNeoplasm stagingProstatic neoplasms

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.